Do the COVID-19 vaccines have specific effects on people with MS that haven’t been observed with other types of vaccines? If so, what is responsible for these differences?
Should people with MS on B-cell depleting therapies be tested for antibodies after being fully vaccinated as part of standard clinical care?
Could the COVID-19 vaccine trigger the onset of MS in those who are already at a higher risk of developing it, such as direct relatives of people diagnosed with MS?
Does the COVID-19 vaccine have the potential to help resolve residual neurological symptoms in people with MS, based on evidence of improvement in fatigue and cognitive issues seen in COVID long haulers?